SCHEMBL303010

SCHEMBL303010

CCC[CH]c1cccc2cc3ccccc3cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
MEN1 O00255 3/20 0.41
CYP1A2 P05177 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
MITF O75030 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
MAPK1 P28482 1/20 0.41
CCR6 P51684 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM4E B2RXH2 2/20 0.36
GAA P10253 2/20 0.36
TLR8 Q9NR97 1/20 0.36
HSD17B10 Q99714 2/20 0.33
HTR2A P28223 2/20 0.33
NQO1 P15559 1/20 0.33
HPGD P15428 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304213 0.90 ALDH1A1 (0.39) ALDH1A1MEN1CYP1A2KMT2AMAPT
SCHEMBL303754 0.88 MAPT (0.38) ALDH1A1MEN1CYP1A2KMT2AMAPT
SCHEMBL304871 0.87 ALDH1A1 (0.44) ALDH1A1MEN1CYP1A2KMT2AMAPT
SCHEMBL303880 0.87 CHAT (0.40) ALDH1A1MEN1CYP1A2KMT2AMAPT
SCHEMBL302974 0.87 CHAT (0.40) ALDH1A1MEN1CYP1A2KMT2AMAPT
SCHEMBL304199 0.87 CHAT (0.40) ALDH1A1MEN1CYP1A2KMT2AMAPT
SCHEMBL302417 0.87 CHAT (0.40) ALDH1A1MEN1CYP1A2KMT2AMAPT
SCHEMBL304211 0.87 CHAT (0.40) ALDH1A1MEN1CYP1A2KMT2AMAPT
SCHEMBL305094 0.87 CHAT (0.40) ALDH1A1MEN1CYP1A2KMT2AMAPT
SCHEMBL305107 0.87 CHAT (0.40) ALDH1A1MEN1CYP1A2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239745-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-07-18 US disclosed
EP-4234609-B1 METHODS FOR PURIFICATION, DETECTION AND QUANTIFICATION OF RESIDUAL PEI-BASED TRANSFECTION REAGENTS POLYPLUS TRANSFECTION (FR) 2024-07-17 EP disclosed
EP-4375280-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-29 EP disclosed
EP-4371984-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-22 EP disclosed
EP-4371985-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-22 EP disclosed
EP-4019607-B1 ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM ESSILOR INT (FR) 2024-05-15 EP disclosed
CN-117881673-A Synthesis method of bilirubin 株式会社毕丽斯 2024-04-12 CN disclosed
CN-117836290-A Synthesis method of bilirubin 株式会社毕丽斯 2024-04-05 CN disclosed
CN-117813301-A Synthesis method of bilirubin 株式会社毕丽斯 2024-04-02 CN disclosed
US-20240052235-A1 ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM ESSILOR INTERNATIONAL (FR) 2024-02-15 US disclosed
EP-1707548-A1 METHOD OF DEUTERATION USING MIXED CATALYST Wako Pure Chemical Industries, Ltd. (JP) 2006-10-04 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed
WO-2006079916-A1 THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION PHARMACIA & UPJOHN COMPANY LLC (US) 2006-08-03 WO disclosed
US-20060116535-A1 Method of deuteration WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-01 US disclosed
US-20060025596-A1 Method for deuteration or tritiation of heterocyclic ring FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2006-02-02 US disclosed
EP-1577280-A1 METHOD OF DEUTERIZATION Wako Pure Chemical Industries, Ltd. (JP) 2005-09-21 EP disclosed
EP-1561741-A1 METHOD FOR DEUTERATION OR TRITIATION OF HETEROCYCLIC RING Wako Pure Chemical Industries, Ltd. (JP) 2005-08-10 EP disclosed
EP-1535889-A1 METHOD OF DEUTERATING AROMATIC RING Wako Pure Chemical Industries, Ltd. (JP) 2005-06-01 EP disclosed
WO-2002000622-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 WO disclosed
US-4104036-A TO IMPROVE OCTANE RATING ATLANTIC RICHFIELD COMPANY (US) 1978-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025596-A1 Method for deuteration or tritiation of heterocyclic ring HRH2, HRH4, HDHD5 ALDH1A1 1829/4885MEN1 2335/4885CYP1A2 624/4885
US-20240052235-A1 ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM EYA3, LAGE3, CDKL5 ALDH1A1 2987/4885MEN1 1931/4885CYP1A2 523/4885
US-20060116535-A1 Method of deuteration ARL1, IDH2, IDH3A ALDH1A1 827/4885MEN1 2083/4885CYP1A2 334/4885
US-20240239745-A1 METHOD FOR SYNTHESIZING BILIRUBIN CYP7A1, UGT1A3, UGT1A1 ALDH1A1 225/4885MEN1 3067/4885CYP1A2 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.